Research analysts who have asked questions during DR REDDYS LABORATORIES earnings calls.
KD
Kunal Dhamesha
Macquarie Group
7 questions for RDY
NM
Neha Manpuria
JPMorgan Chase & Co.
7 questions for RDY
TM
Tushar Manudhane
Motilal Oswal Financial Services
7 questions for RDY
BP
Bino Pathiparampil
Elara Capital
6 questions for RDY
Madhav Marda
Fidelity International
6 questions for RDY
SP
Surya Patra
PhillipCapital
6 questions for RDY
DK
Damayanti Kerai
HSBC
4 questions for RDY
Shashank Krishnakumar
Emkay Global
4 questions for RDY
SS
Shyam Srinivasan
Goldman Sachs
4 questions for RDY
AP
Abdulkader Puranwala
ICICI Securities
3 questions for RDY
AC
Amey Chalke
JM Financial
3 questions for RDY
FP
Foram Parekh
Bank of Baroda
3 questions for RDY
SM
Saion Mukherjee
Nomura
3 questions for RDY
HA
Harith Ahamed
Avendus Spark
2 questions for RDY
KL
Kunal Lakhan
CLSA
2 questions for RDY
VA
Vivek Agrawal
Citi
2 questions for RDY
AQ
Abdul Qadir
ICICI Securities
1 question for RDY
AQ
Abdul Qadir Puranwala
ICICI Securities
1 question for RDY
AW
Aman Witch
Astute Investment Management
1 question for RDY
Ankush Mahajan
Axis Securities
1 question for RDY
BP
Balaji Prasad
Barclays
1 question for RDY
Also covers: ALVO, AMRX, ELAN +7 more
DK
Damyanti Kerai
HSBC Securities
1 question for RDY
G
Gautam
Leo Capital
1 question for RDY
Jainil Shah
JM Financial
1 question for RDY
ND
Nitish Dutt
Burman Capital
1 question for RDY
SA
Shrikant Akolkar
Nuvama Wealth
1 question for RDY
SG
Sumit Gupta
Centrum Capital
1 question for RDY
TA
Tarang Agrawal
Old Bridge Capital Management
1 question for RDY
VA
Vivek Agarwal
Citi
1 question for RDY
Recent press releases and 8-K filings for RDY.
DR REDDYS LABORATORIES LTD Reports Q3 FY26 Results with Revenue Growth and Key Pipeline Progress
RDY
Earnings
Product Launch
New Projects/Investments
- Consolidated revenues reached US$971 million, a 4.4% year-over-year growth, while profit after tax attributable to equity holders declined 14% year-over-year to US$135 million for Q3 FY26. Diluted EPS for the quarter was ₹14.52.
- The company reported an EBITDA of US$228 million with an EBITDA margin of 23.5% (or 24.8% excluding a one-time provision related to new Labour Codes). Gross profit margin was 53.6%.
- DR REDDYS LABORATORIES LTD received marketing authorization for its Semaglutide injection in India and European Commission approval for its Denosumab biosimilar, which has launched in Germany. The company also filed the Biologics License Application (BLA) for its Abatacept biosimilar candidate in December 2025.
- As of December 31, 2025, the company maintained a net cash surplus of US$342 million.
Jan 28, 2026, 11:15 AM
Dr. Reddy's Laboratories to Launch Generic Ozempic in India
RDY
Product Launch
New Projects/Investments
- Dr. Reddy's Laboratories plans to launch a generic injectable version of Novo Nordisk’s semaglutide product Ozempic in India on March 21, 2026.
- The generic is expected to be priced 50–60% below the innovator, potentially around ₹3,600 per pen, to significantly increase affordability for India’s Type 2 diabetes population.
- The company anticipates producing and supplying up to approximately 12 million injectable pens in the first year.
- This launch is part of a broader strategy that includes developing oral semaglutide and a Wegovy-style obesity therapy, with distribution targeted across more than 80 countries.
Jan 21, 2026, 9:27 PM
Dr. Reddy's Laboratories Ltd. Announces Q3 FY2026 Financial Results
RDY
Earnings
Product Launch
Demand Weakening
- Dr. Reddy's Laboratories Ltd. reported consolidated revenues of ₹87,268 Mn for Q3 FY2026, marking a 4.4% increase YoY but a 0.9% decrease QoQ. Profit after Tax attributable to Equity Holders for the quarter was ₹12,098 Mn, representing a 14% decline YoY and 16% decline QoQ. For the nine months ended December 31, 2025 (9MFY26), consolidated revenues grew 8% YoY to ₹260,771 Mn, with profit attributable to equity holders remaining flat YoY at ₹40,649 Mn.
- The Gross Margin for Q3 FY2026 was 53.6%, a decline of 505 basis points YoY and 104 bps QoQ, primarily due to lower Lenalidomide sales, price erosion in North America and Europe, an adverse product mix in the PSAI business, and a one-time provision related to new Labour Codes in India.
- North America revenues for Q3 FY2026 declined 12% YoY and 9% QoQ to ₹29,644 Mn, mainly attributed to lower Lenalidomide sales and higher price erosion. Conversely, Europe revenues grew 20% YoY to ₹14,476 Mn, driven by new generic product launches, growth in the Nicotine Replacement Therapy (NRT) portfolio, and favorable foreign exchange movements.
- Key business developments include the launch of Hevaxin® in India and the marketing authorization for Semaglutide injection in India. The company also received European Commission approval for its denosumab biosimilar but a Complete Response Letter (CRL) from the USFDA for the same product.
Jan 21, 2026, 5:28 PM
Dr. Reddy's Laboratories Reports Q3 2026 Financial Results
RDY
Earnings
Demand Weakening
Product Launch
- DR REDDYS LABORATORIES LTD reported consolidated revenues of Rs. 87,268 million for the three months ended December 31, 2025, marking a 4% increase compared to the same period in the prior year.
- Despite revenue growth, profit for the period decreased by 15% to Rs. 11,896 million for the three months ended December 31, 2025, down from Rs. 14,038 million in the corresponding period of 2024.
- For the nine months ended December 31, 2025, consolidated revenues increased by 8% to Rs. 260,771 million, while the profit for the period saw a 3% decrease to Rs. 40,261 million.
- Revenues from the Global Generics segment in North America experienced a 12% decrease for both the three and nine months ended December 31, 2025, primarily due to a net decrease in sales prices of certain existing products.
- Net cash from operating activities significantly increased to Rs. 41,110 million for the nine months ended December 31, 2025, compared to Rs. 24,432 million in the prior year, mainly driven by a decrease in working capital requirements.
Jan 21, 2026, 4:22 PM
Dr. Reddy's Laboratories Reports Q3 FY26 Financial Results with Revenue Growth and Pipeline Updates
RDY
Earnings
Product Launch
New Projects/Investments
- Dr. Reddy's Laboratories reported Q3 FY26 consolidated revenues of $971 million, representing a 4.4% year-over-year growth, and profit after tax attributable to equity holders of $135 million, a 14% year-over-year decline.
- The company's EBITDA margin stood at 23.5% (24.8% when adjusted for one-time provisions), and diluted EPS was INR 14.52.
- The performance was largely driven by double-digit growth in underlying base businesses (excluding lenalidomide) and favorable foreign exchange rates, which was partially offset by lower lenalidomide sales and continued pricing pressure in US and Europe generics.
- The India business achieved 19% growth (over 17% organic), and the Emerging Markets business grew 32% year-over-year. Conversely, North America generics revenue declined by 16% year-over-year.
- Key pipeline updates include marketing authorization for Semaglutide injection in India (with a launch expected March 21st) and European approval for the Ustekinumab biosimilar; however, the US FDA issued Complete Response Letters for Ustekinumab and Denosumab biosimilars and observations for Rituximab.
Jan 21, 2026, 2:00 PM
Dr. Reddy's Laboratories Ltd. Reports Q3 FY 2026 Earnings
RDY
Earnings
Product Launch
New Projects/Investments
- Consolidated revenues for Q3 FY 2026 reached $971 million, reflecting a 4.4% year-over-year growth but a 0.9% sequential decline.
- The reported EBITDA margin was 23.5%, though the underlying EBITDA margin was 24.8% after adjusting for a one-time provision related to new labor codes.
- Profit after tax attributable to equity holders declined 14% year-over-year and 16% sequentially to $135 million.
- The underlying base businesses (excluding lenalidomide) achieved double-digit growth, driven by strong performance in India (19% year-on-year growth) and emerging markets (32% year-on-year growth), which helped offset lower lenalidomide sales and pricing pressure in the U.S. and Europe generics.
- Key pipeline updates include receiving marketing authorization for Semaglutide injection in India and awaiting Health Canada's response for a potential launch between end of February to May. The company also completed the BLA filing for the IV presentation of abatacept biosimilar in December 2025, with expected US approval by end of calendar 2026 , but received a Complete Response Letter from the U.S. FDA for the Denosumab biosimilar BLA, indicating a delay of at least six months.
Jan 21, 2026, 2:00 PM
Dr. Reddy's Laboratories Reports Q3 FY26 Results with Revenue Growth and Pipeline Progress
RDY
Earnings
Product Launch
New Projects/Investments
- Dr. Reddy's Laboratories reported Q3 FY26 consolidated revenues of $971 million, reflecting a 4.4% year-over-year growth, with a 23.5% reported EBITDA margin (24.8% adjusted for a one-time provision related to new labor codes).
- The company's underlying base business, excluding lenalidomide, delivered double-digit growth, driven by strong performance in India (19% year-over-year growth) and Emerging Markets (32% year-over-year growth).
- North America generics revenue declined by 16% year-over-year primarily due to lower lenalidomide sales, and the company expects zero Revlimid sales from Q4 onwards.
- Key pipeline and strategic advancements include the filing of the Abatacept biosimilar BLA in December 2025, European Commission approval for the Ustekinumab biosimilar, and a strategic collaboration with Immutep for an immunotherapy oncology drug with $20 million upfront.
- The company maintained a net cash surplus of $342 million as of December 31, 2025.
Jan 21, 2026, 2:00 PM
Dr. Reddy's Laboratories Launches Generic Extra-Strength Pataday in U.S.
RDY
Product Launch
- Dr. Reddy's Laboratories Ltd. announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) in the U.S. market on January 14, 2026.
- This product is the generic equivalent of Extra-Strength Pataday® Once Daily Relief, an Antihistamine eye drop, and was approved by the U.S. Food and Drug Administration (USFDA).
- The Pataday® brand recorded approximately $69.9 million in U.S. sales for the 52-week period ending December 27, 2025.
- This launch expands Dr. Reddy's existing over-the-counter eye-care portfolio, which already includes 0.2% and 0.1% strengths of Olopatadine Hydrochloride Ophthalmic Solution USP.
Jan 15, 2026, 11:09 AM
Dr. Reddy's Launches First-to-Market Generic Extra-Strength Pataday® in U.S.
RDY
Product Launch
New Projects/Investments
- Dr. Reddy's Laboratories announced the first-to-market launch of its over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% in the U.S. market.
- This product is the generic equivalent of Extra Strength Pataday® Once-Daily Relief.
- The Pataday® brand had U.S. sales of approximately $69.9 million for the 52 weeks ending December 27, 2025.
Jan 14, 2026, 1:49 PM
Dr. Reddy's Laboratories Subsidiary Receives USFDA Complete Response Letter for Biosimilar Candidate
RDY
Product Launch
New Projects/Investments
- Dr. Reddy's Laboratories SA, a wholly-owned subsidiary, received a Complete Response Letter (CRL) from the United States Food and Drug Administration (USFDA) on December 31, 2025, regarding its Biologics License Application (BLA).
- The CRL pertains to AVT03 (denosumab), a proposed biosimilar candidate to Prolia® & Xgeva®.
- The USFDA's CRL references observations from a pre-license inspection of Alvotech hf’s Reykjavik manufacturing facility.
Dec 31, 2025, 4:15 PM
Quarterly earnings call transcripts for DR REDDYS LABORATORIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more